JP2019085364A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019085364A5 JP2019085364A5 JP2017214460A JP2017214460A JP2019085364A5 JP 2019085364 A5 JP2019085364 A5 JP 2019085364A5 JP 2017214460 A JP2017214460 A JP 2017214460A JP 2017214460 A JP2017214460 A JP 2017214460A JP 2019085364 A5 JP2019085364 A5 JP 2019085364A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- mitochondrial
- compound represented
- active ingredient
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims 4
- 230000004065 mitochondrial dysfunction Effects 0.000 claims 4
- 208000014644 Brain disease Diseases 0.000 claims 3
- 208000032274 Encephalopathy Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000006443 lactic acidosis Diseases 0.000 claims 3
- 208000012268 mitochondrial disease Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000006136 Leigh Disease Diseases 0.000 claims 1
- 208000017507 Leigh syndrome Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017214460A JP6958860B2 (ja) | 2017-11-07 | 2017-11-07 | ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途 |
| US16/759,486 US11369615B2 (en) | 2017-11-07 | 2018-11-07 | Agent for improving mitochondrial dysfunction, preventative or therapeutic agent for diseases or symptoms caused by mitochondrial dysfunction, and applications therefor |
| CN201880085315.7A CN111556750B (zh) | 2017-11-07 | 2018-11-07 | 线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途 |
| EP18876309.8A EP3708161A4 (en) | 2017-11-07 | 2018-11-07 | AGENT FOR IMPROVING MITOCHONDRIAL DYSFUNCTION, PREVENTIVE OR THERAPEUTIC AGENT FOR DISEASES OR SYMPTOMS CAUSED BY MITOCHONDRIAL DYSFUNCTION, AND THEIR APPLICATIONS |
| PCT/JP2018/041354 WO2019093379A1 (ja) | 2017-11-07 | 2018-11-07 | ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017214460A JP6958860B2 (ja) | 2017-11-07 | 2017-11-07 | ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019085364A JP2019085364A (ja) | 2019-06-06 |
| JP2019085364A5 true JP2019085364A5 (enExample) | 2020-11-26 |
| JP6958860B2 JP6958860B2 (ja) | 2021-11-02 |
Family
ID=66437831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017214460A Active JP6958860B2 (ja) | 2017-11-07 | 2017-11-07 | ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11369615B2 (enExample) |
| EP (1) | EP3708161A4 (enExample) |
| JP (1) | JP6958860B2 (enExample) |
| CN (1) | CN111556750B (enExample) |
| WO (1) | WO2019093379A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7265926B2 (ja) | 2019-04-26 | 2023-04-27 | 株式会社Ｎｔｔドコモ | 通信制御装置および通信制御方法 |
| WO2023006954A1 (en) | 2021-07-30 | 2023-02-02 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Asenapine for use in cancer |
| WO2023085420A1 (ja) | 2021-11-15 | 2023-05-19 | 学校法人自治医科大学 | フェロトーシス阻害剤及びその用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56166116A (en) * | 1980-05-26 | 1981-12-21 | Showa Denko Kk | Carcinostatic agent |
| CA2375542A1 (en) * | 1999-06-22 | 2000-12-28 | James A. Dykens | Compositions and methods for assaying subcellular conditions and processes energy transfer |
| HU228783B1 (en) | 2001-07-26 | 2013-05-28 | Greenearth Cleaning | Dry cleaning apparatus and method capable of utilizing a siloxane solvent |
| EP2865385B1 (en) * | 2003-02-04 | 2016-11-16 | Cornell Research Foundation, Inc. | Uses of aromatic-cationic peptide |
| WO2010141932A1 (en) * | 2009-06-05 | 2010-12-09 | Link Medicine Corporation | Aminopyrrolidinone derivatives and uses thereof |
| ES2699077T3 (es) * | 2009-06-12 | 2019-02-07 | Sunovion Pharmaceuticals Inc | Apomorfina sublingual |
| JP2012041314A (ja) * | 2010-08-22 | 2012-03-01 | Kanazawa Univ | 脳腫瘍治療用キット及び脳腫瘍治療方法 |
| EA025033B1 (ru) | 2011-02-11 | 2016-11-30 | Уиста Лэборэтэриз Лтд. | Диаминиевые соли фенотиазина и их применение |
| CA2865316A1 (en) * | 2011-04-28 | 2012-11-01 | Gino Cortopassi | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases |
| EP2739285B9 (en) * | 2011-08-02 | 2019-09-04 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Selective inhibition of malt1 protease by phenothiazine derivatives |
| US20140275045A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| CA2939219C (en) * | 2014-02-11 | 2023-02-28 | Mitokinin Llc | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
| CA2920272A1 (en) * | 2015-02-13 | 2016-08-13 | Stealth Biotherapeutics Corp | Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof to treat and prevent mitochondrial diseases and conditions |
| JP6763691B2 (ja) | 2016-05-30 | 2020-09-30 | 上野製薬株式会社 | 熱可塑性樹脂組成物 |
-
2017
- 2017-11-07 JP JP2017214460A patent/JP6958860B2/ja active Active
-
2018
- 2018-11-07 EP EP18876309.8A patent/EP3708161A4/en not_active Withdrawn
- 2018-11-07 US US16/759,486 patent/US11369615B2/en active Active
- 2018-11-07 WO PCT/JP2018/041354 patent/WO2019093379A1/ja not_active Ceased
- 2018-11-07 CN CN201880085315.7A patent/CN111556750B/zh not_active Expired - Fee Related